

Realizing Competitive Advantage with a Life Sciences Data Sharing Culture

2nd in a Series on Data Insights of Life Sciences Leaders from the Cognizant-Informatica Roundtable

Accelerating business outcomes by collaborating, innovating, and democratizing insights across the modern pharma enterprise

Even a decade ago, the idea of freely exchanging data with competitors — or even some internal departments — would have been dismissed out of hand.

Keeping commercial information strictly under wraps used to be the norm in every sector. Now as more and more studies support the business benefits of sharing data, attitudes are changing.

Gartner reported that “By 2023, organizations that promoted data sharing will outperform their peers on most business value metrics,” and “Through 2023, organizations that can instill digital trust will be able to participate in 50% more ecosystems, expanding revenue generation opportunities.”¹

Those findings are testament to the idea that data only becomes a business asset when stakeholders across a business can use it. On paper it makes sense, but it only works in practice if non-technical users can understand data, trust it and derive insights from it on their own; this is accomplished all while ensuring data is secure and protected, and used only by authorized users and for approved purposes.

The tension between data ambition and reality is now stretching the life sciences industry. Stakeholder expectations have skyrocketed thanks to digital transformation and demand for more effective treatments that meet the needs of more discrete patient populations.

All these factors are driving a push to create collaborative data platforms based on free exchange of data and independent (e.g., non-IT) use of analytics.

^{1,2} Gartner®, “Why Situational Trust is Key to Data Sharing for Business Value,” Lydia Clougherty Jones, August 11, 2022.

Only 15%

By 2024, most organizations will attempt trust-based data sharing programs, but only 15% will succeed and outperform their peers on most business metrics.²

To justify the investment in data platform capabilities, the data platform must deliver business benefits in key areas:



Grow Revenue

Expand market share and grow revenue by enabling digital engagement strategies that enhance commercial operations and identify and develop high-value relationships with health care providers and health care organizations.



Accelerate R&D

Speed discovery of new products and therapies, improve the design and cost-efficiency of clinical trials and promote appropriate data sharing with AI-powered integration of massive volumes of new and existing data to support advanced analytics.



Enhance Manufacturing Efficiency

Promote manufacturing and supply chain efficiency by automating business processes to reduce manual effort, improve quality, eliminate rework, and enable self-service.



Make Compliance Easier

Reduce the effort, cost, time and risk associated with regulatory compliance by automating processes and providing end-to-end visibility and auditability.



Facilitate M&A

Grow market share and gain efficiencies through M&A with a shared data platform to help consolidate back office and administrative functions and eliminate duplicate and redundant applications and infrastructure

50% More

Through 2023, organizations that can instill digital trust will be able to participate in 50% more ecosystems, expanding revenue generation opportunities.³

Can All Five Be Achieved?

For a recent roundtable, Informatica and Cognizant invited senior data leaders from some of Europe's biggest life sciences organizations to consider the issue of data democratization and the barriers to spreading the benefits of data-driven decision-making across the wider business.

What follows is a summary of the major issues and discussion threads, which include recommendations that can help life sciences data leaders move their organizations towards collaborative data democracy.

³ Gartner®, "Why Situational Trust is Key to Data Sharing for Business Value," Lydia Clougherty Jones, August 11, 2022.

The Big Issues

Creating an Organizational Data Culture

Culture and data literacy are the two most pervasive roadblocks for successful rollout of data initiatives. Roundtable participants discussed how those barriers could be overcome, with a focus on the importance of speaking one-to-one with line-of-business owners to understand their analytics needs and objectives.

It was noted that data leaders may sometimes find themselves in a mediating role, managing different perspectives on the full pharma product lifecycle and the variables that can impact KPIs at different stages.

Make Data a Cornerstone of Business Culture

Securing buy-in across a global life sciences organization with a complex ecosystem of systems, suppliers, locations and facilities means mapping a data strategy with multiple stakeholders in mind, and awareness of specific local and regional regulation and business needs. Without it, any collaborative data platform is unlikely to succeed in implementation.

Driving a data-driven culture within a life sciences organization may also require embedding new values. This means that data-driven decision-making should be seen as the default approach. This requires commitment at all levels in the organization, amplified through communication, training and leadership-by-example at the executive level.

Once a new set of data-first values has been communicated, instilling new data-driven habits comes next. To make data a cornerstone of business culture, pharma firms need to invest across four operational pillars: people, platforms, partners and processes.



“When we delivered useful insights to commercial teams, they were much more open to sharing their own information. What we still see however is people staying within their comfort area and not thinking about how things might be improved beyond their department. In too many situations the business user is still thinking, ‘to address my particular use case I only need this kind of information.’”

Deciding on Data Owners

Agreeing who in the organization should own data processes and procedures is one area participants found particularly challenging. While different departments and business units often express enthusiasm for having access to data and gaining the power to generate their own insights, finding someone to 'wear the data hat' in each stakeholder group can be difficult.

The default position for many companies is to 'leave data ownership to IT.' However, it was agreed that this is traditional thinking that runs counter to ideas about data self-service or democratizing data across the wider organization.

One participant said data teams should own or even sponsor any data initiatives. In a data sharing culture, participants discussed the value of having business users take ownership and having data teams adopt the role of simply clarifying what they need from analytics.

Trust is Key

Establishing data stewards in each department or business grouping is vital if a nascent data sharing culture is going to reach maturity. Pharma companies capture or generate a quantum of data every day, but like all large enterprises, they sometimes struggle to use their data appropriately, consistently and safely.

The key issue is trust, and this is where data governance and data stewardship overlap. Data stewards manage the practical coordination and implementation of data policies. They also act as a liaison between business users and IT to help manage organizational data.

Collaboration solutions like data analytics consoles can help life sciences data leaders build a single source of truth about patient and trial data so that stakeholders can make informed data management decisions.

Data stewards can see who uses data, the processes that produce and consume it, the policies that apply to it, the systems that hold it, the quality of data within those systems and any business risk associated with it.

They can even share their own knowledge of data usage to ensure that information is always accurate and up to date.

"I think what's needed is to find commonalities. We've had some success bringing business domain owners together so they can help us identify the rules and transformations that help us create data products that are cross-usable."

Data Industrialization: Fantasy or Reality?

Concepts like data self-service and data-as-a-product are fundamental to the creation of a data sharing culture. Once data-centric processes and ways of working have been established, handing business users independent access to data is the logical outcome. Searchable, Amazon-like data marketplaces are the logical way to achieve this – but in life sciences the practical challenges to building in-house self-service platforms are considerable.

Participants discussed issues like lack of control over quality: “I can collect simple market data from different countries and harmonize it to create data products ... but the quality and the granularity; this is still for the countries to decide.”

One pharma company reported successful experiments with multi-country analytics dashboards that make regional and global use cases for data easier to identify: “We realized that many national teams were having similar problems (with data) but using different narratives to discuss them.”

Another had moved from a centralized IT team producing database solutions to decentralized and country teams, but ‘with limited adoption’ due to lack of data skillsets.

Self-service Capabilities Power User Insights

An industrialized approach to data means embracing a product mindset that makes data and models easy and appealing to use. It should extend self-service capabilities to the whole life sciences R&D ecosystem and deliver them in a user-friendly way. The ambition should be to unlock the business benefits of data across the pharma value chain and free non-technical users to power insights of their own.

Any self-service capability must support the wider shift to data-driven digital transformation in life sciences and be accessible enterprise-wide. That calls for two kinds of capabilities:

- 1 To support the distinct needs of different users and lines of business
- 2 To deal with the sheer volume and variety of data that needs to be governed in different applications and systems.

“Governance is essential if you consider the requirements of something like GDPR. I can tell the commercial side that I can industrialize things and they can benefit from having a solution for one country. To enroll all the countries, however, there’s a prerequisite that everyone follows the same governance rules. That needs to happen for this to be scalable.”

Governance and Trust

A common thread throughout the roundtable was the vital role of governance as an enabler of corporate data sharing culture. Trust, quality and effective stewardship of R&D data was seen by participants as foundational to any data initiative in life sciences.

Establishing principles of data quality and automating data management had the effect of enhancing trust between different stakeholders and facilitated sharing between them.

The Importance of Data Stewardship

As life sciences firms look to reap more rewards from digital transformation, rigorous stewardship of clinical trial and commercial data is crucial. Maintaining the principles of data governance and implementing strategies to improve healthcare data quality, use and exchange can lead to better patient safety, interoperability and clinical efficiency.

Leading medical associations continue to stress the importance of effective data management and appropriate changes to clinical processes given the growing need for accurate, timely information for high-quality patient care.



“This is one of the challenges for organizations with lots of different datasets, and lots of people responsible for different data sets. How do you create a legal framework and reach agreements inside the organization on how to deal with the responsibility? Because GDPR would see it one way while our framework for defining data, data ownership and data governance might see it in a different way.”

The Great Enabler: A Unified Clinical Platform?

Pharma continues to rely on a blend of technology products and services from a variety of vendors. The gaps between these systems, however, can complicate governance, create process fragmentation, add costs and create administrative delays.

To overcome these issues, participants discussed their own experiences in developing in-house solutions for sharing data and analytics across the enterprise. Practical examples were discussed where a single platform had been developed, allowing multiple business users to execute basic analytics tasks on their own or in collaboration with others.

Participants reported early progress, for example, feedback from business users who reported they were better able to locate data sets, identify opportunities or flag areas of concern.

However, barriers to full adoption remain:

- Lack of **data skill sets**
- Inconsistent **data policies and procedures**
- **Lack of clarity over data** ownership at the country, business unit or department level
- **Data siloes** and **multiple** repositories
- Concerns about **data quality**

Conclusion

Even as life sciences firms begin to embrace the notion of a data sharing culture and its benefits, there is a risk of adding complexity rather than reducing it. Data democratization could mean having an extended list of data stewards and owners. Could that give rise to tensions and make data governance harder to achieve?


Having a coherent governance solution in place across the pharma enterprise can alleviate those concerns, while also addressing the barriers to full adoption of unified data platforms.

It's crucial for life sciences firms to reimagine and automate data management processes to drive efficiency and unlock new insights. They will have to invest in promising technologies and should consider risk-sharing relationships with other companies – both in their own supply chain and beyond, to the wider healthcare ecosystem.

⁴ Gartner®, How to Create an Optimal Organization Model for Data and Analytics, Jorgen Heizenberg, 27 Feb 2023

70%

By 2025, 70% of public companies that outperform competitors on key financial metrics will also report being data and analytics centric.⁴





Informatica®



cognizant®

About Cognizant and Informatica

Rapid advances in technology are raising expectations across healthcare. Life sciences organizations are being pushed to work faster and more efficiently. Digital transformation offers the hope of accelerating clinical development and targeting treatments at ever-more discreet patient populations. Connected digital solutions that facilitate data sharing and full enterprise democratization will be critical in helping organizations through this transformation.

Cognizant and Informatica have partnered to help life sciences companies through the transition. It stems from shared corporate values and a drive to assist customers in achieving their digital goals. This insights paper is part of a webinar series designed to help pharma go beyond technology adoption and achieve meaningful, patient-centered transformation.

For further information, please contact:

Richard Cramer

Chief Strategist, Healthcare and Life Sciences
Informatica

rcramer@informatica.com

Sean Heshmat

Cognizant GGM (Ex-US) Data and AI Head
Cognizant

Sean.Heshmat@Cognizant.com

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

Informatica (NYSE: INFA) brings data to life by empowering businesses to realize the transformative power of their most critical assets. When properly unlocked, data becomes a living and trusted resource that is democratized across the organization, turning chaos into clarity. Through the Informatica Intelligent Data Management Cloud™, companies are driving bigger ideas, creating improved processes and reducing costs. Powered by CLAIRES®, our AI engine, it's the only cloud dedicated to managing data of any type, pattern, complexity or workload across any location – all on a single platform, with a simple and flexible consumption-based pricing model. Informatica. Where data comes to life.

About Cognizant

Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life.

See how at www.cognizant.com or @cognizant.

IN19-0327-4551

© Copyright Informatica LLC 2023. Informatica and the Informatica logo are trademarks or registered trademarks of Informatica LLC in the United States and other countries. A current list of Informatica trademarks is available on the web at <https://www.informatica.com/trademarks.html>. Other company and product names may be trade names or trademarks of their respective owners. The information in this documentation is subject to change without notice and provided "AS IS" without warranty of any kind, express or implied.

informatica.com

Want to learn more?

Cognizant and Informatica partnership in support of life sciences companies at www.informatica.com/cognizant

Or visit www.informatica.com/life-sciences